JERUSALEM, April 29, 2013 /PRNewswire/ —

Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a developer of oral delivery systems of drugs currently administered by injection, announced today that its abstract, entitled “Oral insulin capsules toward management of Type 1 diabetes mellitus,” will be presented at the Global Technology Community Diabetes Summit 2013. The poster will be presented today, April 29^th, by Dr. Miriam Kidron, Oramed’s Chief Scientific Officer, between 5:00pm-7:00pm EDT during the poster session and evening reception in the Ballroom Foyer of the Hyatt Regency Hotel.

The work summarizes the results of Oramed’s key clinical studies assessing the safety and efficacy of its oral insulin formulation (ORMD-0801) in patients with Type 1 diabetes (T1DM) and in a subpopulation of T1DM patients who experience frequent and unpredictable swings in their blood sugar levels. ORMD-0801 was safe and well tolerated and effectively kept blood sugar levels in check, when administered before meals. In addition, the blood sugar readings of unstable T1DM patients more frequently fell within the normal range, when compared to those of the pretreatment monitoring sessions. The presented results demonstrate that Oramed’s technology effectively delivers insulin without compromising its bioactivity, and serve as an impetus to realize the therapeutic potential of ORMD-0801 in regulating T1DM.

The poster will be available on Oramed’s website later this evening, following the poster presentation time, at: http://oramed.com/index.php?page=13

About The Global Technology Community Diabetes Summit

The GTC Diabetes Summit is the only diabetes conference that provides delegates the opportunity to facilitate discussions and collaborations among affiliations (industry, academia, government) that can lead to the advancement of therapeutics and development of drugs/treatments for diabetes, and hopefully one day a cure. In addition the conference will provide updated educational research on various novel targets, therapeutics, developments, and technologies; regulatory guidance; case studies on successful and/or unsuccessful clinical trials; and other relevant insights that can help delegates advance their own research and therapeutics.

For more information on the Summit, please visit their website at http://www.gtcbio.com/conference/diabetes-summit-overview

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines currently delivered via injection. Established in 2006, Oramed’s technology is based on over 30 years of research by top research scientists at Jerusalem’s Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801) currently approaching Phase 2 clinical trials under an Investigational New Drug application with the U.S. Food and Drug Administration, and with its oral exenatide capsule (ORMD-0901; a GLP-1 analog), currently approaching Phase 2a trials. The company’s corporate and R&D headquarters are based in Jerusalem.

For more information, the content of which is not part of this press release, please visit http://www.oramed.com.

The company’s fact sheet, the content of which is not part of this press release, can be viewed here.

Forward-looking statements: This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and federal securities laws. For example, we are using forward-looking statements when we discuss how the results of our study demonstrate that our technology effectively delivers insulin without compromising its bioactivity, and serve as an impetus to realize the therapeutic potential of ORMD-0801 in regulating T1DM, or when we discuss our oral insulin and oral exenatide candidates approaching Phase 2 clinical trials under U.S. IND and 2a clinical trials, respectively. These forward-looking statements are based on the current expectations of the management of Oramed only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval

or patent protection for our product candidates; competition from other pharmaceutical or biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from competition; laboratory results that do not translate to equally good results in real settings; our patents may not be sufficient; and final that products may harm recipients, all of which could cause the actual results or performance of Oramed to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Oramed undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Oramed, reference is made to Oramed’s reports filed from time to time with the Securities and Exchange Commission.

Company Contact:
Oramed Pharmaceuticals
Aviva Sherman
Cell: +972-54-792-4438
Office: +972-2-566-0001
Email: aviva@oramed.com

SOURCE Oramed Pharmaceuticals Inc.